AstraNu's Bell Labs Spinout Puts a $3.5M Bet on Chip-Scale Medical Imaging

The Nokia Bell Labs spinout is commercializing integrated photonics to make high-resolution OCT imaging accessible for device makers, starting with otology.

About AstraNu

Published

The promise of non-invasive imaging in medicine has long been shadowed by a trade-off. High-resolution scans like CT or MRI offer a detailed look inside the body, but they are expensive, bulky, and often involve ionizing radiation or sedation. Optical Coherence Tomography (OCT), a technique that uses light to create micrometer-resolution cross-sections, has been a gentler alternative for decades, particularly in ophthalmology. Yet the systems remain large, complex, and costly, limiting their deployment beyond specialized clinics. A new spinout from Nokia Bell Labs, AstraNu, is betting that a fundamental hardware redesign can break that trade-off for a new class of devices [Nokia, May 2025].

The Wedge: An Engine, Not an Appliance

AstraNu’s core product is not a finished medical scanner for a hospital. It is an integrated OCT engine module, a chip-scale hardware component designed for medical device manufacturers to embed into their own products. By applying integrated photonics,the same technology that miniaturized components for the telecom industry,the company claims it can combine the required lasers, detectors, and optics onto a single chip [ROI-NJ, Oct 2026]. The reported result is a component described as 10 times smaller and cheaper than traditional OCT assemblies [ROI-NJ, Oct 2026]. For device makers, this could mean adding high-resolution, non-invasive 3D and 4D imaging capabilities to handheld or point-of-care tools without the traditional footprint or price tag. The initial clinical target is otology, specifically imaging for hearing and middle-ear conditions like otitis media, where clearer visualization could reduce misdiagnosis and the need for more invasive diagnostic steps [Converge Digest, May 2025].

The Bell Labs Pedigree and Seed Capital

The company’s origins and technical credibility are tightly linked to its parentage. AstraNu was launched in 2025 through a collaboration between Nokia and venture firm Celesta Capital to commercialize imaging technology developed at Bell Labs [Nokia, May 2025]. The founding team is led by CEO Trevor Hawkins, a healthcare technology executive Nokia credits with decades of experience scaling diagnostic startups, alongside the technology’s co-inventors, Michael Eggleston and Bibek Samanta, who helped incubate the project at the famed research lab [Nokia, May 2025]. This heritage likely played a role in attracting a $3.5 million seed round, closed in November 2026 and led by Celesta Capital with co-investment from the New Jersey Innovation Evergreen Fund [PRNewswire, Nov 2026]. The capital is earmarked for commercializing the chip-scale engine.

The company’s leadership and technical foundation reflect its hardware-centric, research-intensive bet.

Role Name Background & Note
CEO Trevor Hawkins, PhD Experienced healthcare-tech executive; led the spinout from Nokia [Nokia, May 2025].
Co-inventor & Technical Lead Michael Eggleston, PhD Research Group Leader at Nokia Bell Labs; co-inventor of the integrated OCT tech [Nokia, May 2025].
Co-inventor & Technical Lead Bibek Samanta, PhD Co-inventor of the technology; helped develop it at Bell Labs [Nokia, May 2025].

Navigating a Regulated Hardware Pathway

AstraNu’s business model,selling a component, not a finished device,creates a distinct regulatory and commercial pathway. The company will not seek FDA clearance for a diagnostic device itself. That burden, and opportunity, falls to its customers, the medical device original equipment manufacturers (OEMs) who integrate the engine into their own cleared or approved products. This shifts the go-to-market challenge from direct clinical sales to deep technical partnerships and proving the module’s performance and reliability in a regulated design environment. The long-term vision extends beyond otology into other areas like ophthalmology, and even beyond healthcare to industrial metrology, though the current public focus remains firmly on medical imaging [LinkedIn].

The Counterfactual: Integration Versus Adoption

The bet is ambitious, and its success hinges on several interlocking factors beyond pure technical miniaturization. The company must convince device makers that the performance of its integrated module matches or exceeds that of bulkier, proven systems, a claim that will require rigorous, peer-reviewed validation. Furthermore, adoption depends on those OEMs having the will and capital to develop new product lines around the engine, a process measured in years, not quarters. While the technology may be 10x smaller, the sales cycle into the conservative medical device industry is not. Finally, while the potential to reduce unnecessary CT scans is a compelling patient benefit, realizing it requires the new class of devices to achieve widespread clinical use and trust.

For patients with chronic middle-ear infections or hearing disorders, the standard of care today often involves a physical exam with an otoscope, which provides only a surface view, followed by a decision point. If deeper visualization is needed, the next step is typically a referral for a CT scan, which involves radiation, or an MRI, which is costly and may require sedation, especially for children. This diagnostic journey can be slow, anxiety-inducing, and expose patients to unnecessary risk. AstraNu’s ultimate impact rests on enabling a new tier of tools that could bring high-fidelity imaging into the primary care or ENT specialist’s office, making detailed, non-invasive visualization a routine part of the initial assessment. That is the patient outcome that makes the engineering challenge worth pursuing.

Sources

  1. [Nokia, May 2025] Nokia and Celesta Capital launch Astranu to advance healthcare imaging technology | https://www.nokia.com/about-us/news/releases/2025/05/15/nokia-and-celesta-capital-launch-astranu-to-advance-healthcare-imaging-technology/
  2. [Converge Digest, May 2025] Nokia and Celesta Capital Spin Out Astranu to Pioneer 3D Imaging | https://convergedigest.com/nokia-and-celesta-capital-spin-out-astranu-to-pioneer-3d-imaging
  3. [ROI-NJ, October 2026] New Jersey Economic Development Authority invests $16.5M to support 8 startups | https://www.roi-nj.com/2026/10/19/politics/new-jersey-economic-development-authority-invests-16-5m-to-support-8-startups/
  4. [PRNewswire, Nov 2026] AstraNu Closes $3.5 Million Seed Round Led by Celesta Capital to Commercialize Chip-Scale Optical Imaging Engine | https://www.prnewswire.com/news-releases/astranu-closes-3-5-million-seed-round-led-by-celesta-capital-to-commercialize-chip-scale-optical-imaging-engine-302941615.html
  5. [LinkedIn] Astranu company page | https://www.linkedin.com/company/astranu

Read on Startuply.vc